Skip to content

Telo Genomics Technology to Detect & Profile Multiple Myeloma MRD

Multiple Myeloma

The purpose :

Detect and profile Multiple myeloma Measurable Residual Disease(MRD) prognostics for monitoring post-transplant Multiple Myeloma (MM) Patients receiving maintenance therapy.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

* Confirmed MM diagnosis
* Transplant eligible patients in a first remission
* Known MRD level detected by ClonoSeq (other IMWG recognized methodologies can be also employed)
* Availability of deidentified patient's demographic and clinical follow up data
* Receiving standard of care treatment
* Able to provide informed consent

Exclusion Criteria:

* Failure to meet inclusion criteria

Study Location

Jewish General Hospital
Jewish General Hospital
Montreal, Quebec
Canada

Contact Study Team

Primary Contact

Rayan Kaedbey, MD

[email protected]
514 340 8222
Study Sponsored By
Sir Mortimer B. Davis - Jewish General Hospital
Participants Required
More Information
Study ID: NCT05530096